Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial.
暂无分享,去创建一个
B. Melichar | L. Hart | I. Ray-Coquard | V. Diéras | D. Yardley | D. Dorer | C. Turner | M. Barve | A. Melnyk | P. Dodion | M. Seiler